Autologous Hematopoietic Peripheral Blood Stem Cells

DB17067InvestigationalCell transplant therapies

Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.

Mechanism: Pharmacologically active on Hematopoietic progenitor cell antigen CD34
Curator reviewed

Resolves to

Targets

P28906CD34

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Autologous Hematopoietic Peripheral Blood Stem Cells, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account